Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

libragen Celebrates Success in European PolyModE Project

Published: Tuesday, October 01, 2013
Last Updated: Tuesday, October 01, 2013
Bookmark and Share
Biocatalysis and metagenomics used for generation of improved hydrocolloids with potential therapeutic properties.

libragen has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.

libragen is internationally recognized for its expertise in biocatalysis and metagenomics (the study of whole genetic material from environmental samples) and is regularly engaged as a partner in such large research programs. As a key member of this collaboration - which included both academic and industrial partners - libragen successfully developed a high-throughput functional screen for the detection of sulphatase activity and metagenomic screening libraries using environmental samples. As a result of this combined approach, 10 novel sulphatase producers were identified from more than 20000 screened metagenomic clones and the partners triumphed in identifying, characterizing and optimizing novel enzymes for the modification of all six targeted polysaccharides overall.

libragen’s biocatalysis project leader, Dr. Rob Ter Halle, will be presenting how biocatalysis offers significant advantages in comparison to classical chemistry in terms of selectivity, specificity and yield, on 10 October at 14:00 at the Industrial Biotech Forum during Biotechnica 2013, Hannover, (8-10 October). His talk, entitled “Applied biocatalysis to obtain novel glyco-conjugates”, will detail how libragen’s bespoke contract research services increased both manufacturing profitability and competitiveness in the context of a real-world example – the synthesis of the cosmetic ingredient glucosyl conjugate of caffeic acid. In this example, libragen’s advanced technology and expertise yielded a remarkably efficient process founded on the principles of green chemistry. Only water was used as a solvent, no derivatization was required and all reagents were obtained from natural, renewable sources. The end-product has vastly improved solubility and oxidative stability compared to caffeic acid, yielding a higher performance compound that is now efficiently produced at a scale of several hundred kilos, while saving both time and money.

Biotechnica delegates can also visit booth E59 to discover how libragen’s expertise in biocatalysis and metagenomic technologies can be applied to enhance their specific application.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DSM and LibraGen Sign Agreement to Co-Develop Transaminases for Production of Chiral Amines
DSM and LibraGen, a bacterial diversity-based process and discovery specialist, announced today that they have signed an agreement to co-develop new omega-transaminases for production of chiral amines.
Tuesday, September 16, 2008
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos